Ann Rehabil Med.  2016 Feb;40(1):66-73. 10.5535/arm.2016.40.1.66.

Delay of the Blink Reflex in Patients Receiving Platinum-Analogue Chemotherapy

• Park KY
• Park YS
• Park YH
• Chang HJ
• Cho ES
• Kim SH
• Kim WJ

• KMID: 2155167
• DOI: http://doi.org/10.5535/arm.2016.40.1.66

Abstract

OBJECTIVE
To investigate the presence of cranial neuropathy in patients with platinum-analogue chemotherapy using electrodiagnostic evaluations.
METHODS
Thirty-nine patients whose chemotherapy was completed within a month and 40 control subjects were enrolled in the study. Electrodiagnostic evaluation was performed using sensory and motor nerve conduction studies and blink reflex studies, in addition to the two-point discrimination test.
RESULTS
The chemotherapy group had significantly longer latencies of bilateral R1 responses (left p<0.001; right p<0.001) and greater distance in two-point discrimination (p<0.001) compared to the control group. In the subgroup with peripheral polyneuropathy, the left R1 (p=0.01), both R2i (left p=0.02; right p=0.03) and the left R2c (p=0.02) were prolonged relative to those without the polyneuropathy, and both R1 (left p<0.001; right p<0.001), R2i (left p=0.01; right p=0.03), and the left R2c (p=0.01) were prolonged relative to the controls. On the other hand, the subgroup without the polyneuropathy showed only prolongation of both R1 (left p=0.006; right p<0.001) relative to the controls.
CONCLUSION
In the present study, comparison of blink reflex and two-point discrimination showed the likelihood of subclinical cranial neuropathy following platinum-analogue chemotherapy. Cranial neuropathy caused by platinum agents was more profound in patients with peripheral polyneuropathy and may be dependent on the cumulative dose of the drug. The blink reflex may be of value in detecting subclinical cranial neuropathy in patients undergoing platinum-analogue chemotherapy.

Keyword

Platinum compounds; Chemotherapy; Blink; Cranial nerve

MeSH Terms

Blinking*
Cranial Nerve Diseases
Cranial Nerves
Discrimination (Psychology)
Drug Therapy*
Hand
Humans
Neural Conduction
Platinum
Platinum Compounds
Polyneuropathies
Platinum
Platinum Compounds

Reference

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7:573–584. PMID: 17625587.

2. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008; 44:1507–1515. PMID: 18571399.

3. Mollman JE. Cisplatin neurotoxicity. N Engl J Med. 1990; 322:126–127. PMID: 2152970.

4. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995; 13:228–244. PMID: 8573296.

5. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003; 30(4 Suppl 15):5–13. PMID: 14523789.

6. Verschraegen C, Conrad CA, Hong WK. Subacute encephalopathic toxicity of cisplatin. Lung Cancer. 1995; 13:305–309. PMID: 8719070.

7. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009; 63:761–767. PMID: 19034447.

8. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005; 64:199–207. PMID: 15668414.

9. Higby DJ, Wallace HJ Jr, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974; 33:1219–1215. PMID: 4856724.

10. de Cos Escuin JS, Delgado IU, Rodriguez JC, Lopez MJ, Vicente CD, Miranda JA. Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors. Arch Bronconeumol. 2007; 43:358–365. PMID: 17663887.

11. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23–30. PMID: 14665611.

12. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract. 2011; 2011:843019. PMID: 22312559.

13. Toker E, Yenice O, Ogut MS. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS. 2004; 8:69–71. PMID: 14970804.

14. Vogel H, Horoupian DS. Filamentous degeneration of neurons: a possible feature of cytosine arabinoside neurotoxicity. Cancer. 1993; 71:1303–1308. PMID: 8435808.

15. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998; 9:443–447. PMID: 9636837.

16. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis. 2002; 9:220–233. PMID: 11895373.

17. Guney F, Demir O, Gonen MS. Blink reflex alterations in diabetic patients with or without polyneuropathy. Int J Neurosci. 2008; 118:1287–1298. PMID: 18698511.

18. Esteban A. A neurophysiological approach to brainstem reflexes: blink reflex. Neurophysiol Clin. 1999; 29:7–38. PMID: 10093816.

19. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992; 84:364–371. PMID: 1441917.

20. Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht CJ. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol. 1992; 239:143–146. PMID: 1315383.

21. Barajon I, Bersani M, Quartu M, Del Fiacco M, Cavaletti G, Holst JJ, et al. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol. 1996; 138:93–104. PMID: 8593900.

22. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014; 40:872–882. PMID: 24830939.

23. Elkholy SH, Hosny HM, Shalaby NM, El-Hadidy RA, Abd El-Rahim NT, Mohamed MM. Blink reflex in type 2 diabetes mellitus. J Clin Neurophysiol. 2014; 31:552–555. PMID: 25462142.

24. Resende LA, Caramori JC, Kimaid PA, Barretti P. Blink reflex in end-stage-renal disease patients undergoing hemodialysis. J Electromyogr Kinesiol. 2002; 12:159–163. PMID: 11955988.

25. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002; 249:9–17. PMID: 11954874.